Gout is the most common inflammatory arthritis in the United Kingdom, affecting an estimated 2.5% of adults — approximately 1.5 million people, according to the UK Gout Society and data published in the Annals of the Rheumatic Diseases. Despite being eminently treatable, gout remains poorly managed: fewer than half of patients on urate-lowering therapy achieve target serum urate levels, and acute flares continue to drive GP and A&E attendances that could often be managed in the community.

Community pharmacists encounter gout patients at two critical moments: during the acute flare (seeking pain relief) and during long-term prophylaxis (collecting allopurinol or febuxostat prescriptions). Both interactions offer opportunities to improve outcomes.

Acute gout: what pharmacists can supply and advise

OTC treatment options

NSAIDs are the mainstay of acute gout management per NICE guideline CG2.2, but many gout patients have comorbidities (renal impairment, cardiovascular disease, peptic ulcer history) that preclude NSAID use. When NSAIDs are contraindicated, pharmacists should advise the patient to see their GP promptly for colchicine or corticosteroid prescription.

Practical advice for acute flares

• Rest the affected joint — gout most commonly affects the first metatarsophalangeal joint (big toe), but can also affect ankles, knees, wrists and fingers
• Apply ice wrapped in a cloth for 20 minutes at a time
• Keep the joint elevated and avoid pressure (even bedsheets on an affected toe can be excruciating)
• Stay hydrated — adequate fluid intake supports renal urate excretion
• Avoid aspirin during acute flares — low-dose aspirin reduces renal urate clearance and can worsen attacks

When paracetamol is not enough

Paracetamol alone is generally insufficient for acute gout pain. NICE guidance does not recommend paracetamol as monotherapy for gout flares. Patients presenting with severe joint pain and swelling who cannot take NSAIDs should be referred for same-day GP assessment.

Long-term management: allopurinol counselling

Allopurinol is the most commonly prescribed urate-lowering therapy in the UK. NICE recommends offering urate-lowering therapy to patients who have had two or more gout attacks in 12 months, have tophi, have chronic kidney disease, or use diuretics.

Key counselling points for allopurinol

• Start low, go slow: typical starting dose is 100mg daily, titrated upward every four weeks until serum urate is below 300 μmol/L (or 360 μmol/L without tophi)
• Paradoxical flares are common: initiating allopurinol can trigger acute gout attacks in the first weeks to months. This does NOT mean the medicine is not working — patients should continue treatment and manage flares with NSAIDs or colchicine
• Colchicine prophylaxis: NICE recommends colchicine 500mcg once or twice daily for up to six months when starting allopurinol, to reduce the risk of initiation flares
• Renal dose adjustment: allopurinol requires dose reduction in renal impairment. Check the patient's last eGFR if available
• Hypersensitivity: rare but serious — rash, fever and eosinophilia (drug reaction with eosinophilia and systemic symptoms, DRESS) requires immediate discontinuation and urgent medical review

Febuxostat

Febuxostat is a second-line option when allopurinol is contraindicated or not tolerated. Key counselling: cardiovascular safety monitoring (MHRA safety alert following the CARES trial), liver function monitoring, and the same initiation-flare warning as allopurinol.

Lifestyle advice pharmacists can provide

• Dietary triggers: red meat, organ meats, shellfish and beer are high in purines. Moderate intake rather than strict elimination is the evidence-based approach
• Alcohol: beer and spirits are most strongly associated with gout attacks. Wine appears to carry lower risk, but moderation applies
• Sugar-sweetened drinks: fructose metabolism generates uric acid. Advise limiting sugary drinks
• Dairy: low-fat dairy products may be protective — the orotic acid and casein in milk promote renal urate excretion
• Weight management: obesity is a significant risk factor. Gradual weight loss reduces serum urate; crash dieting can paradoxically trigger flares
• Hydration: 2–3 litres of fluid daily supports urate excretion

Red flags requiring referral

Pharmacists should refer patients to their GP when:

• An acute flare does not respond to OTC NSAIDs within 48 hours
• The patient has two or more flares in a year and is not on urate-lowering therapy
• Joint swelling is accompanied by fever or skin redness spreading beyond the joint (possible septic arthritis — urgent referral)
• The patient has visible tophi (chalky deposits under the skin near joints)
• Renal function is declining in a patient on allopurinol

The pharmacy opportunity

Gout is one of the conditions where pharmacy intervention can make a measurable difference. The acute flare is often managed with OTC medicines that the pharmacist supplies directly. The long-term therapy requires adherence counselling that the monthly dispensing interaction is ideally suited to deliver.

According to PharmSee's tracker, 1,715 pharmacy vacancies remain active across England as of April 2026 — the workforce providing these consultations is stretched. For pharmacists looking for roles in rheumatology or musculoskeletal services, PharmSee's job search tracks specialist vacancies, and the salary guide covers NHS Band 7–8a clinical pharmacist pay.

Data sources: NICE CG2.2 (Gout), UK Gout Society prevalence estimates, BSR Guideline for the Management of Gout (2017), MHRA febuxostat safety alert, PharmSee vacancy tracker (April 2026, 1,715 active roles).